Brief: Valneva Provides Update On Recommendations For Use Of Ixchiq® In United Kingdom
13/02/2026 17:02
Feb 13 (Reuters) - Valneva SE VLS.PA: PROVIDES UPDATE ON RECOMMENDATIONS FOR USE OF IXCHIQ® IN UNITED KINGDOM MHRA CONFIRMS FAVORABLE PROFILE FOR AGES 18-59 WITHOUT CONTRAINDICATIONS UPDATED PI INCLUDES RESTRICTIONS FOR INDIVIDUALS OVER 60 Source text: ID:nGNESqLDS Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency